top of page

Transforming gene therapy with an advanced AAV delivery platform

Enhanced specificity and accelerated development through modular, post-manufacture enzymatic AAV vector modification.

capsids white.png

We are developing an innovative technology that equips AAV vectors with molecules to accurately target the intended tissues.


Efficient delivery of recombinant AAV vector cargo to the right cells remains a key challenge for successful gene therapies.

​

Our platform technology enables more efficient delivery and thus can help reduce unintended side effects.

TAVIRA THERAPEUTICS WAS CO-FOUNDED BY

gi_logo.webp

Els Henckaerts, MD PhD

Benjamien Moeyaert, PhD

Veronick Benoy, PhD

Vibha Kiran Tamboli, PhD

Inge Van Hove, PhD

INVESTORS

gi_logo.webp
Gemma Frisius.png
DNA.png
“We strive to create new gene therapies that will provide breakthrough treatments for genetic disorders that are currently incurable.”

Prof Els Henckaerts
co-founder Tavira Tx

bottom of page